Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
17 March 2017
|
| In: |
Leukemia and lymphoma
Year: 2017, Jahrgang: 58, Heft: 10, Pages: 2501-2504 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428194.2017.1298755 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1080/10428194.2017.1298755
|
| Verfasserangaben: | Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi H. Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng & Douglas Joshua |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575444771 | ||
| 003 | DE-627 | ||
| 005 | 20220814144415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180523s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2017.1298755 |2 doi | |
| 035 | |a (DE-627)1575444771 | ||
| 035 | |a (DE-576)505444771 | ||
| 035 | |a (DE-599)BSZ505444771 | ||
| 035 | |a (OCoLC)1341009992 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ludwig, Heinz |e VerfasserIn |0 (DE-588)1078703272 |0 (DE-627)83916565X |0 (DE-576)451629620 |4 aut | |
| 245 | 1 | 0 | |a Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma |b results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup |c Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi H. Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng & Douglas Joshua |
| 264 | 1 | |c 17 March 2017 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.05.2018 | ||
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 58(2017), 10, Seite 2501-2504 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup |
| 773 | 1 | 8 | |g volume:58 |g year:2017 |g number:10 |g pages:2501-2504 |g extent:4 |a Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428194.2017.1298755 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180523 | ||
| 993 | |a Editorial | ||
| 994 | |a 2017 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1575444771 |e 3010005652 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma","title_sort":"Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma","subtitle":"results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup"}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"17 March 2017"}],"note":["Gesehen am 23.05.2018"],"id":{"doi":["10.1080/10428194.2017.1298755"],"eki":["1575444771"]},"relHost":[{"language":["eng"],"part":{"extent":"4","volume":"58","pages":"2501-2504","year":"2017","issue":"10","text":"58(2017), 10, Seite 2501-2504"},"recId":"324746237","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["324746237"],"issn":["1029-2403"],"zdb":["2030637-4"]},"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}],"origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedKey":"1989","dateIssuedDisp":"1989-"}],"note":["Gesehen am 08.09.15"],"pubHistory":["1.1989/90 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupLeukemia and lymphoma"}],"recId":"1575444771","physDesc":[{"extent":"4 S."}],"name":{"displayForm":["Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, Roman Hájek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosiñol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi H. Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng & Douglas Joshua"]},"person":[{"display":"Ludwig, Heinz","family":"Ludwig","given":"Heinz","role":"aut"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut"}],"language":["eng"]} | ||
| SRT | |a LUDWIGHEINCARFILZOMI1720 | ||